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Abstract: Lurasidone is a new atypical antipsychotic in the benzoisothiazoles class of chemicals. 
Like most second-generation antipsychotics it is a full antagonist at dopa  mine D2 and serotonin 
5-HT2A receptors, and is a partial agonist at 5-HT1A receptors, a property shared by some but 
not all older agents. It has much greater affinity for 5-HT7 subtype receptors than other atypical 
antipsychotics. Pharmacokinetic studies showed that lurasidone is reasonably rapidly absorbed, 
with bioavailability appearing to be increased by food. Lurasidone undergoes extensive metabo-
lism to a number of metabolites, some of which retain pharmacological activities. Metabolism 
is mainly by CYP3A4, resulting in steady-state concentrations that vary between individuals 
and are potentially affected by strong inducers and inhibitors of this enzyme. Short-term   clinical 
trials have demonstrated the efficacy of lurasidone in acute schizophrenia, with doses of 40 
and 80 mg/day giving significant improvements from baseline in the PANSS and BPRS scores. 
The most common adverse events are nausea, vomiting, akathisia, dizziness, and sedation, with 
minimal increases in the risk of developing metabolic syndrome. Lurasidone did not raise the 
risk of QTc interval prolongation, although additional studies are required. Long-term trials 
are also needed to assess the risk of new-onset diabetes. Ongoing trials in patients with bipolar 
disorder are being completed but, again, efficacy and safety have been investigated only in a 
few short-term clinical trials.
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Introduction
Schizophrenia is one of the most debilitating psychiatric disorders and affects about 
1% of the population worldwide.1 It causes recurring and progressive episodes of 
positive symptoms (eg, hallucination, delusions), negative symptoms (eg, alogia, 
anhedonia), disturbed cognitive function (eg, impaired attention), and aggressive/
hostile and depressive/anxious abnormalities.2,3 It is associated with an increased risk 
of mortality and imposes a huge financial burden on society.4,5 Optimal treatment could 
lighten this burden,6 but it is challenging to develop antipsychotic drugs that stabilize 
the patient and reduce the symptoms and likelihood of relapse.
Until recently, pharmacological treatment of schizophrenia was based on 
  conventional agents such as chlorpromazine and haloperidol (generally called first-
generation antipsychotics) whose action is thought to be the result of their high-affinity 
dopamine D2 receptor antagonism.7 Although efficacious against positive symptoms, 
these agents have limited efficacy against negative symptoms and can induce various 
severe adverse effects including extrapyramidal symptoms (EPS), which also   probably 
reflect   blockage of D2 receptors. Nowadays, however, these drugs have been replaced 
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by second-generation antipsychotics (also called atypical 
agents, whose prototype is clozapine), due to a more accept-
able   tolerability profile.8,9 While each drug of this atypical 
class has its own receptor profile, most of them show higher 
affinity for serotonin type 2A (5-HT2A) than D2 receptors, 
which have been linked to their better effects on the nega-
tive symptoms of schizophrenia.10,11 Also, they all share the 
propensity to cause minimal EPS at doses that are clinically 
active against positive symptoms.12–14
Nevertheless, D2-related treatment-stopping side effects 
such as weight gain, lipid dysregulation, and hyperglycemia 
can still arise with some of these antipsychotics,15–17 and 
they may be associated with cardiovascular adverse events, 
particularly prolongation of cardiac action potential QT 
intervals, an effect which may cause cardiac arrhythmias.18 
Recent pragmatic or effectiveness clinical trials such as the 
clinical antipsychotic trials of intervention effectiveness 
(CATIE) and cost utility of the latest antipsychotic drug in 
schizophrenia study (CUtLASS) have challenged the view of 
the advantages of second-generation antipsychotics over con-
ventional agents,19–21 although this conclusion is debated.22,23 
Efforts are continuing to identify new molecules with a bal-
ance of effects on dopamine and 5-HT receptors, as these 
would result in a better therapeutic profile. This has led to 
some new antipsychotic options,24,25 including the benziso-
thiazole derivative lurasidone, which at the time of writing 
is the most recently introduced chemical.26
Recent reviews have described the in vitro and in vivo 
neuropharmacology of lurasidone, and have summarized 
the trials examining its therapeutic efficacy and tolerability 
in the management of schizophrenia and schizoaffective 
disorder.27–29 Others have discussed its pharmacokinetic 
and metabolic profiles and compared these to other recently 
released antipsychotics.30 This review further examines the 
clinical pharmacology, pharmacokinetics, efficacy, and 
safety of this antipsychotic.
Methods
This review is based on a literature search on the international 
database PubMed. The keywords used were “lurasidone” 
and “schizophrenia”; no date constraints were utilized. 
Data were also collected from the product labeling avail-
able at the manufacturer’s website (www.ds-pharma.com). 
A query “lurasidone” on the ClinicalTrials.gov website 
(www.clinicaltrials.gov) and the FDA’s website (www.fda.
gov) did not result in the identification any additional com-
pleted clinical studies. Twenty-nine records that matched the 
two keywords were originally identified from PubMed, with 
three of these being clinical trials (one phase II trial and two 
phase III trials).
Pharmacological profile
Chemically, lurasidone or (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-
(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl] cyclohexy-
lmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione 
hydrochloride is structurally related to perospirone and 
ziprasidone (see Figure 1 for chemical structures), and older 
benzisothiazoles with antipsychotic activity. In a similar 
chemical class are the benzisoxazole derivatives risperidone, 
its active metabolite paliperidone, and iloperidone. Besides 
the chemical structure, benzisothiazoles and benzisoxazoles 
shares some minor metabolic pathways.31
As with its structurally related drugs and many other 
atypical antipsychotics, lurasidone has high affinity for the 
dopamine D2 and 5-HT2A receptors. However, it has the 
highest affinity of any atypical antipsychotic for the 5-HT7 
receptor, the blockade of which may also contribute to its 
antipsychotic effects.32 Experimental studies support the posi-
tive effects of 5-HT7 antagonists on cognitive impairment,33,34 
memory,35 and mood symptoms.36
Lurasidone also has high affinity for the 5-HT1A subtype, 
with which it interacts as a partial agonist in a similar way 
to some but not all antipsychotics (eg, the benzisothiazoles 
perospirone and ziprasidone, but not the benzisoxazoles 
risperidone and iloperidone).32 5-HT1A receptors, widely 
expressed in the central nervous system and upregulated in 
the frontal cortex, have been implicated in the enhancement of 
cognitive function in pharmacological models37 and patients 
with schizophrenia; the stimulation of these receptors could 
normalize frontal cortex function and reduce side effects 
induced by dopamine D2 receptor blockade such as EPS, 
including dystonia and diskinesia, abolishing catalepsy and 
the blockade of pituitary-located D2 receptors that control the 
prolactine release that has been observed experimentally and 
clinically with older atypical antipsychotics.37–39 The so-called 
“third-generation” antipsychotic aripiprazole is also a 5-HT1A 
receptor partial antagonist but, unlike benzisothiazole deriva-
tives, it combines this activity with D2 partial antagonism and 
also exhibits high-affinity D3 antagonism.40
Lurasidone has affinity for α2c-adrenergic receptors, 
which are also implicated in the enhancement of   cognitive 
function, and low affinity for α1-adrenergic receptors, which 
suggests that it will have a low propensity for causing 
orthostatic hypotension. It has minimal affinity for 5-HT2C 
receptors, so would not be expected to cause weight gain. 
It has negligible affinity for histamine H1 and muscarinic 
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receptors, which are linked to sedation and weight gain, and 
have negative cognitive effects.32
In vivo lurasidone and some of its metabolites were simi-
lar to other antipsychotics in their efficacy in animal models 
predictive of antipsychotic activity.32 Improved cognitive 
effects and mood stabilization were also observed in various 
learning and memory impairment models in rats. Evaluation 
of the secondary pharmacodynamic properties of lurasidone 
showed only very weak potential for drug-associated EPS 
and central nervous system (CNS) depressive effects such 
as exaggeration of anesthesia, muscle relaxation, and inhi-
bition of motor coordination. Findings are summarized in 
Table 1.27,32,41
Pharmacokinetics
Lurasidone is rapidly absorbed, reaching peak concentrations 
within 1.5–3 hours (tmax) after single and multiple oral doses. 
Its pharmacokinetics were linear in the range of 20 to 160 mg 
in healthy and schizophrenic subjects, but intersubject vari-
ability was high in both populations (30%–50% in healthy 
subjects, 30%–60% in patients with schizophrenia) in terms 
of plasma maximum concentrations (Cmax) and area under 
the curve (AUC) over the dosing interval (AUCτ).41 Based 
on the amount of lurasidone that was excreted unchanged 
in urine in fasting healthy subjects, systemic bioavailability 
was between 9% and 19%. However, absorption increased 
when the drug was taken with food; in a study comparing 
the steady-state pharmacokinetics of lurasidone 120 mg with 
meals of various calorie and fat content versus the fasted 
state, lurasidone exposure as measured by AUC and Cmax 
increased two- to three-fold in the presence of food, although 
there was no significant difference in exposure based on the 
calorie/fat content of the meal. These findings have been 
reviewed elsewhere.28,29,42
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Figure 1 Chemical structures of lurasidone, ziprasidone, and perospirone. R = H is 1-(1,2-benzisothiazol-3-yl)-piperazine (BITP).
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Once absorbed, lurasidone is similar to most lipophilic 
antipsychotics in that it extensively distributes in tissues. It 
rapidly enters the CNS, with a dose-dependent increase in 
D2 receptor occupancy up to 60 mg (77.4%–84.3%, depend-
ing on the region) with no further increases after 80 mg, at 
about the tmax of plasma concentrations in healthy subjects.27 
The mean apparent volume of distribution greatly exceeded 
the body water volume, averaging 6173 L at the recom-
mended starting dose of 40 mg. Lurasidone has high binding 
to human plasma albumin and alpha-1-glycoprotein ($99%). 
The mean fraction of lurasidone distributed in red blood cells 
was approximately 12% in vivo in healthy subjects.
In animal studies, lurasidone penetrated the placental bar-
rier and distributed into the fetus, and was excreted in milk 
during lactation. The manufacturer’s prescribing information 
should therefore be consulted for administration guidelines 
for pregnant and nursing women.42
Elimination is essentially by metabolism, primarily 
involving CYP3A4-mediated oxidative N-dealkylation, 
hydroxylation of the norbornane ring or cyclohexane ring, 
S-oxidation of the isothiazolyl ring, reductive cleavage of the 
isothiazole ring followed by S-methylation, and combinations 
of two or more of these pathways. The two main metabolites, 
the acidic derivative ID-20219 and its hydroxylated deriva-
tive ID-20220, had negligible affinity for the rat D2 receptor 
and the human D2L receptor, or for the rat 5-HT2 and human 
5-HT1A, 5-HT2A, and 5-HT7 receptors.
Besides ID-20219, lurasidone N-dealkylation yields 
to 1-(1,2-benzisothiazol-3-yl)-piperazine (ID-11614 or 
BITP), a metabolite common to perospirone and ziprasidone 
 ( Figure 1). This metabolite also had poor in vitro activity 
at the D2 and 5-HT2 receptors and no antipsychotic-like 
action in preclinical tests although it concentrated in rat 
brain, raising the acetylcholine content (see reference 31 for 
review). BITP shares some of the in vivo pharmacodynamic 
properties of lurasidone in rodent and non-rodent species.26 
After oral doses of radiolabeled lurasidone, exposure to 
ID-11614 varied depending on the species and dose, rang-
ing from approximately 12% in rats and dogs at 50 mg/kg 
to 100% in monkeys at 10 mg/kg of the plasma exposure to 
lurasidone, but there is little and only incomplete informa-
tion on its pharmacokinetics compared with the parent drug 
in humans.26
Two other metabolites, the exo-hydroxy derivative 
ID-14283 and the endo-hydroxy derivative ID-14326 (see 
Figure 2 for chemical structures), showed affinity for D2 
and 5-HT2A comparable to lurasidone. Both also had high 
affinity for human receptor subtypes 5-HT1A and 5-HT7, 
similar to lurasidone’s affinity for these subtypes. In vitro 
functional activity studies suggested that both ID-14283 and 
ID-14326 were partial agonists of the human 5-HT1A receptor 
and potent antagonists of human D2 L and 5-HT7 receptors, 
further suggesting that hydroxylation at position 5 or 6 of 
lurasidone’s norbornane skeleton had little influence on its 
Table 1 Main pharmacological properties of lurasidone
Primary pharmacology
In vitro studies
    High affinity for human D2L, serotonin 5-HT2A, 5HT1A and 5HT7 
receptors.a
    Partial agonism at human 5HT1A and antagonism at human D2L and 
5-HT7 receptors.a
    High affinity for human α2c-adrenoceptorsa, and relatively high affinity 
for α1, α2, α2A adrenoreceptor types.
    Little binding affinity for 5-HT3, 5-HT4, noradrenaline β, β1, β2, 
adenosine A1, A2, benzodiazepine, cholecystokinin CCKA, CCKB, 
L-type Ca2+ channel, N-type Ca2+ channel, GABAA, glutamate AMPA, 
kainate, NMDA, glycine, histamine H1, muscarin M1, M2, nicotine, 
opiate, sigma, 5-HT uptake sites, and dopamine uptake sites.
Antipsychotic-like activity
    Inhibition of methamphetamine-induced hyperactivity in rats,a 
apomorphine-induced stereotyped behavior in rats, apomorphine-
induced climbing behavior in mice and conditioned avoidance 
response in rats.
    Antagonism of central 5-HT2 receptors, as shown by dose-dependent 
inhibition of tryptamine-induced clonic forepaw seizurea,b and 
p-chloroamphetamine-induced hyperthermia in mice and rats.
Mood-stabilizing effects
  Inhibition of conditioned fear stress-induced freezing behavior in rats.
    Increased punished drinking response (number of shocks received) in 
Vogel’s water lick conflict test.
    Increased social interaction time spent by pairs of naive rats under 
brightly illuminated conditions in the social interaction test.
Cognitive effects
    Improvement of learning and of memory impairment induced by the 
NMDA-receptor antagonist MK-801 and memory impairment induced 
by the muscarinic receptor antagonist scopolamine in rats.
Effects on monoamine metabolism
    Enhancement of the contents of dopamine metabolites DOPAC 
and HvA and boosted dopamine turnover in the frontal cortex and 
striatum, like other antipsychotic agents.
Secondary pharmacology
Potential extrapyramidal symptom liability
    No cataleptogenic activity in either mice or rats, whereas comparator 
antipsychotics dose-dependently induced catalepsy.
    No significant effects on the pole-descending time and forepaw 
reaction time in animal models, unlike comparator antipsychotics.
Potential for CNS depression
    weaker effects than comparator antipsychotics on spontaneous 
locomotor activity, hexobarbital-induced anesthesia, muscle relaxation 
and motor coordination and MES-induced seizures in animal models.
Notes: aThese properties are shared by metabolites ID-14283 and ID-14326, and 
bmetabolite ID-11614 or 1-(1,2-benzisothiazol-3-yl)-piperazine.
Abbreviations: DOPAC, 3, 4-dihydroxyphenylacetic acid; HvA, homovanillic acid; 
MES, maximal electric shock; NMDA, N-methyl-D-aspartate. 
Adapted from references 27, 32, 41.
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Figure 2 The active metabolites of lurasidone. BITP = 1-(1,2-benzisothiazol-3-yl)-piperazine.
neuropharmacological action.42 After oral doses of 20 to 
80 mg/day of lurasidone hydrochloride in Japanese male and 
female patients with schizophrenia, the mean exposure (Cmax 
and AUC24) to ID-14283 and ID-14326 was approximately 
24% and 3%, respectively, of that to lurasidone – this indi-
cates that these metabolites, particularly ID-14283, contribute 
to the antipsychotic action of lurasidone. As with the parent 
compound, the two metabolites showed similar differences in 
exposure under fed as opposed to fasting conditions.28 Both 
are slightly less bound to human plasma proteins than the par-
ent drug (98.8%);42 however, brain uptake and concentrations 
compared to lurasidone have not yet been reported.
In excretion studies in healthy subjects, after a single dose 
of radiolabeled lurasidone was administered approximately 
80% of total radioactivity was recovered in feces and 9% in 
urine.42 In single-dose pharmacokinetic studies in healthy 
subjects (doses ,100 mg/day), the mean terminal half-life 
ranged from 12.2 to 18.3 hours in some studies, but at steady 
state in patients with schizophrenia it rose to between 28.8 
and 37.4 hours.27 Thus, after repeated oral doses in schizo-
phrenic patients, steady-state concentrations of lurasidone 
were achieved within 7 days.42
Special populations
Healthy elderly men had approximately 31% lower 
  lurasidone Cmax than younger males, but their AUCs were 
similar.27 Exposure to lurasidone and its active metabolites 
in elderly patients with psychosis and in younger subjects
was similar after 20 mg/day lurasidone hydrochloride. 
Therefore, as with most second-generation antipsychotics, 
no dose adjustment is needed in elderly people.42 Exposure 
in women was 18% higher than in men, which indicates that 
oral clearance was lower in women, as assessed by popula-
tion pharmacokinetic analysis. Asians had 40% less clear-
ance than Caucasians, but these differences in exposure are 
also not expected to be clinically relevant.41,42 Lurasidone 
pharmacokinetics have not been examined in pediatric and 
adolescent patients.
Renal impairment led to increased mean exposure to 
  lurasidone after oral doses of 40 mg lurasidone   hydrochloride. 
Compared with healthy matched controls, mild, moderate, 
and severe renal disease led to mean Cmax increases of 40%, 
92%, and 54%, and AUC increases of 53%, 91%, and 
100%, respectively. The mean t1/2 was also prolonged with 
increasing severity of renal impairment.41 The manufacturer 
recommends that doses should not exceed 40 mg in moderate 
and severe renal-impaired patients. This same dose should 
also not be exceeded in patients with moderate or severe 
hepatic disease.42 In a single-dose study with 20 mg lurasi-
done hydrochloride, mean AUC(0-last) was 1.5 times greater 
in subjects with mild hepatic impairment, 1.7 times greater 
in subjects with moderate impairment, and 3 times greater in 
those with severe impairment, compared to healthy matched 
subjects. Mean Cmax was 1.3, 1.2, and 1.3 times higher for 
mild, moderate, and severely impaired patients, respectively, 
when compared to healthy matched subjects. The mean t1/2 
for patients with moderate hepatic impairment was greater 
than in healthy subjects (112 versus 93 hours, but in healthy 
subjects this value is much higher than in previous studies); 
there are no data for severe hepatic impairment. Increased 
exposure to active metabolites and their elimination t1/2 were 
also observed with increasing severity of hepatic impairment 
compared with the healthy matched control group, although 
results were not detailed.41
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Drug interactions
The manufacturer recommends caution when lurasidone 
is co-administered with CYP3A4 inducers or inhibitors; 
ketoconazole (400 mg daily), for example, increased 
exposure to lurasidone by 7–9 times in healthy subjects 
taking 10 mg, while diltiazepam (240 mg/day), a moderate 
CYP3A4 inhibitor, doubled the AUC and Cmax of the parent 
drug and its active metabolite ID-14283 in healthy subjects. 
The CYP3A4 inducer rifampin (600 mg/day) reduced expo-
sure to lurasidone by as much as 85% in a single-dose study 
(40 mg) in healthy subjects.42
Lurasidone itself is a moderate inhibitor of CYP3A4 in 
human tissue preparations and in vivo at steady state 
(120 mg/day) it increased the Cmax and AUC(0–24) of midazo-
lam (5 mg) by approximately 21% and 44%, respectively, 
although these changes are considered clinically irrelevant. 
Similarly, oral contraceptives containing ethinyl estradiol 
and norelgestromin resulted in negligible changes in Cmax 
and AUC when coadministered with lurasidone (40 mg/day). 
In vitro studies using human tissue preparations suggested 
that clinically relevant concentrations of lurasidone also 
moderately inhibited CYP2C8-, CYP2C9-, CYP2C19-, and 
CYP2B6-mediated reactions.41,42
Lurasidone has not been shown to affect protein binding 
of biperiden, flunitrazepam, haloperidol, or diazepam, the 
few drugs that have been studied in vitro. Similarly, it did 
not affect protein binding of concomitant highly-bound drugs 
with affinity for albumin and alpha-1-glycoprotein.41
Although lurasidone is not a substrate of the   P-glycoprotein 
(P-gp; and nor is its active metabolite ID-14283), it had 
an inhibitory effect on digoxin transport in vitro in cells 
expressing human P-gp.27 However, co-administration at 
steady state (120 mg/day) with a single dose of digoxin 
(0.25 mg) increased the Cmax and AUC24 of digoxin by only 
about 10%.42
No interaction was observed when lurasidone (120 mg) 
was administered with lithium (600 mg twice daily) to 
patients with schizophrenia, schizophreniform, or schizoaf-
fective disorder.
Efficacy in clinical studies
Table 2 summarizes the nine clinical studies investigating 
the efficacy of lurasidone for schizophrenia in adults (mean 
age 39 years, range 18 to 72 years).28,29,41,43–47 Seven of these 
studies were short-term (6-week) randomized, double-blind 
placebo-controlled studies, with three of these seven being 
phase II trials and four being phase III trials. The FDA 
used five studies for drug approval.41 An active comparator 
  (haloperidol, quetiapine, or olanzapine) was used in four 
trials.41,45 Data on efficacy was also available from a 3-week 
study that compared lurasidone with ziprasidone in stable 
patients with schizophrenia or schizoaffective disorders,43 
and from an 8-week dose–response trial in inpatients and 
outpatients with schizophrenia.48
A dose–response study of lurasidone in which 20, 40, or 
80 mg/day was administered indicated that 40 and 80 mg/day 
were associated with significant improvements from baseline 
in the positive and negative syndrome scale (PANSS) and 
brief psychiatric rating scale (BPRS) scores, and achieved 
significantly better results than 20 mg/day.48 Some studies 
used changes in clinical global impression severity (CGI-S) 
score, clinical global impression improvement (CGI-I) 
score, and PANSS subscale score as secondary endpoints. 
At 6 weeks, efficacy primary and secondary measures were 
consistently in favor of lurasidone 80 mg/day over placebo 
(except in one failed trial). Two studies also showed efficacy 
for doses of 40 and 120 mg/day (see Table 2).41,43–45
A pooled analysis based on a five-factor model of 
schizophrenia from four short-term, double-blind, placebo-
controlled studies demonstrated that at 6 weeks, lurasidone 
was significantly better than a placebo in improving all five 
PANSS factors (positive, negative, disorganized thought, 
hostility, and depression/anxiety scores).49 Time of onset 
(in the first 3 to 7 days) and trajectory of improvement 
was similar across the 40–120 mg/day dose range when 
PANSS scores were considered. No differences sugges-
tive of a dose–response relationship were found in GCI-S 
for 40–120 mg/day. Early onset, by day 7, was reported 
in the changes in CGI-S scores for 80–120 mg/day. This 
pooled analysis found no clear dose-response relationship, 
and generalizability was limited by the characteristics of 
patients enrolled in the studies: there were high percentages 
of patients who were white (32  %–52%), male (69%–79%), 
and aged between 37 and 41 years.
In a 3-week study directly comparing lurasidone 
120 mg/day and ziprasidone 160 mg/day in stable outpatients 
with schizophrenia, efficacy was similar, with an earlier onset 
of improvement in PANSS total score by day 7.43,47 This study 
also evaluated the cognitive effect of lurasidone and found no 
between-group differences on a performance-based cognitive 
functioning assessment battery. Unlike ziprasidone, however, 
lurasidone showed significant within-group improvement 
from baseline on the matrices consensus cognitive battery 
(MCBB) composite score and on the schizophrenia cogni-
tion rating scale (SCoRS). Another trial was considered 
failed because neither lurasidone (20, 40, or 80 mg/day) nor 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
160
Caccia et alNeuropsychiatric Disease and Treatment 2012:8
T
a
b
l
e
 
2
 
S
u
m
m
a
r
y
 
o
f
 
m
a
i
n
 
e
f
fi
c
a
c
y
 
l
u
r
a
s
i
d
o
n
e
 
c
l
i
n
i
c
a
l
 
s
t
u
d
i
e
s
S
t
u
d
y
 
(
y
e
a
r
 
o
f
 
p
u
b
l
i
c
a
t
i
o
n
)
T
y
p
e
 
o
f
 
s
t
u
d
y
 
a
n
d
 
d
u
r
a
t
i
o
n
 
(
w
e
e
k
s
)
D
i
a
g
n
o
s
e
s
 
a
n
d
 
n
u
m
b
e
r
 
o
f
 
r
a
n
d
o
m
i
s
e
d
 
p
a
t
i
e
n
t
s
L
u
r
a
s
i
d
o
n
e
 
r
e
g
i
m
e
n
 
(
n
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
)
A
c
t
i
v
e
 
c
o
m
p
a
r
a
t
o
r
 
r
e
g
i
m
e
n
 
(
n
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
)
P
l
a
c
e
b
o
 
(
n
u
m
b
e
r
 
 
o
f
 
p
a
t
i
e
n
t
s
)
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
M
a
i
n
 
e
f
fi
c
a
c
y
 
r
e
s
u
l
t
s
 
(
p
r
i
m
a
r
y
 
o
u
t
c
o
m
e
s
)
S
h
o
r
t
-
t
e
r
m
 
e
f
fi
c
a
c
y
 
s
t
u
d
i
e
s
P
o
t
k
i
n
,
 
e
t
 
a
l
4
3
R
a
n
d
o
m
i
s
e
d
,
 
d
o
u
b
l
e
-
 
b
l
i
n
d
,
 
c
o
n
t
r
o
l
l
e
d
 
(
z
i
p
r
a
s
i
d
o
n
e
)
 
t
r
i
a
l
2
1
 
d
a
y
s
A
d
u
l
t
 
o
u
t
p
a
t
i
e
n
t
s
 
w
h
o
 
m
e
e
t
 
D
S
M
 
I
v
 
c
r
i
t
e
r
i
a
 
f
o
r
 
s
c
h
i
z
o
p
h
r
e
n
i
a
 
o
r
 
 
s
c
h
i
z
o
a
f
f
e
c
t
i
v
e
 
d
i
s
o
r
d
e
r
s
,
z
i
p
r
a
s
i
d
o
n
e
1
2
0
 
m
g
 
o
n
c
e
 
 
d
a
i
l
y
 
N
 
=
 
1
5
0
Z
i
p
r
a
s
i
d
o
n
e
 
(
Z
)
 
8
0
 
m
g
 
B
I
D
N
 
=
 
1
5
1
–
M
A
T
R
I
C
S
 
C
o
n
s
e
n
s
u
s
 
C
o
g
n
i
t
i
v
e
 
B
a
t
t
e
r
y
 
(
M
C
C
B
)
,
 
i
n
t
e
r
v
i
e
w
-
 
b
a
s
e
d
 
a
s
s
e
s
s
m
e
n
t
 
o
f
 
c
o
g
n
i
t
i
v
e
 
f
u
n
c
t
i
o
n
i
n
g
,
 
a
n
d
 
S
c
h
i
z
o
p
h
r
e
n
i
a
 
C
o
g
n
i
t
i
o
n
 
R
a
t
i
n
g
 
S
c
a
l
e
 
(
S
C
o
R
S
)
A
 
s
t
a
t
i
s
t
i
c
a
l
 
t
r
e
n
d
 
(
P
 
=
 
0
.
0
5
8
)
 
f
o
r
 
l
u
r
a
s
i
d
o
n
e
 
t
o
 
i
m
p
r
o
v
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
S
C
o
R
S
.
N
o
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
 
b
e
t
w
e
e
n
 
t
r
e
a
t
m
e
n
t
 
f
o
r
 
c
h
a
n
g
e
s
 
o
n
 
t
h
e
 
M
C
C
B
 
s
c
o
r
e
N
a
k
a
m
u
r
a
 
M
,
 
 
e
t
 
a
l
4
4
R
a
n
d
o
m
i
s
e
d
,
 
d
o
u
b
l
e
-
 
b
l
i
n
d
,
 
p
l
a
c
e
b
o
-
 
c
o
n
t
r
o
l
l
e
d
 
t
r
i
a
l
6
-
w
e
e
k
P
a
t
i
e
n
t
s
 
h
o
s
p
i
t
a
l
i
z
e
d
 
f
o
r
 
a
c
u
t
e
 
e
x
a
c
e
r
b
a
t
i
o
n
 
o
f
 
 
D
S
M
-
I
v
 
s
c
h
i
z
o
p
h
r
e
n
i
a
1
8
0
 
p
a
t
i
e
n
t
s
8
0
 
m
g
/
d
a
y
 
 
(
fi
x
e
d
 
d
o
s
e
)
 
N
 
=
 
9
0
–
P
l
a
c
e
b
o
N
 
=
 
9
0
P
r
i
m
a
r
y
:
 
B
P
R
S
 
t
o
t
a
l
 
s
c
o
r
e
S
e
c
o
n
d
a
r
y
:
 
P
A
N
S
S
 
t
o
t
a
l
 
s
c
o
r
e
,
C
l
i
n
i
c
a
l
 
G
l
o
b
a
l
 
I
m
p
r
e
s
s
i
o
n
-
 
S
e
v
e
r
i
t
y
 
s
c
o
r
e
s
I
m
p
r
o
v
e
m
e
n
t
 
o
n
 
t
h
e
 
B
P
R
S
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
L
O
C
F
)
:
L
:
 
-
8
.
9
 
(
±
1
.
3
)
 
P
 
=
 
0
.
0
1
2
P
:
 
-
4
.
2
 
(
±
1
.
3
)
D
1
0
5
0
0
0
6
4
1
R
a
n
d
o
m
i
s
e
d
,
 
d
o
u
b
l
e
-
 
b
l
i
n
d
,
 
p
l
a
c
e
b
o
-
 
c
o
n
t
r
o
l
l
e
d
6
-
w
e
e
k
P
a
t
i
e
n
t
s
 
h
o
s
p
i
t
a
l
i
z
e
d
 
f
o
r
 
a
c
u
t
e
 
e
x
a
c
e
r
b
a
t
i
o
n
 
o
f
 
D
S
M
-
I
v
 
s
c
h
i
z
o
p
h
r
e
n
i
a
1
4
9
 
p
a
t
i
e
n
t
s
4
0
 
m
g
/
d
a
y
N
 
=
 
5
0
1
2
0
 
m
g
/
d
a
y
N
 
=
 
4
9
–
P
l
a
c
e
b
o
N
 
=
 
9
0
P
r
i
m
a
r
y
:
 
B
P
R
S
 
t
o
t
a
l
 
s
c
o
r
e
S
e
c
o
n
d
a
r
y
:
 
P
A
N
S
S
 
t
o
t
a
l
 
s
c
o
r
e
;
C
l
i
n
i
c
a
l
 
G
l
o
b
a
l
 
I
m
p
r
e
s
s
i
o
n
-
 
S
e
v
e
r
i
t
y
 
s
c
o
r
e
;
 
C
l
i
n
i
c
a
l
 
G
l
o
b
a
l
 
I
m
p
r
e
s
s
i
o
n
-
I
m
p
r
o
v
e
m
e
n
t
 
s
c
o
r
e
I
m
p
r
o
v
e
m
e
n
t
 
o
n
 
t
h
e
 
B
P
R
S
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
L
O
C
F
)
:
L
 
4
0
 
m
g
/
d
a
y
:
 
-
9
.
4
 
(
±
1
.
6
)
 
P
 
=
 
0
.
0
2
L
 
1
2
0
 
m
g
/
d
a
y
:
 
-
1
1
.
3
 
(
±
1
.
6
)
 
P
 
=
 
0
.
0
0
4
P
:
 
-
3
.
8
 
(
±
1
.
6
)
D
1
0
5
0
2
2
9
,
P
E
A
R
L
 
1
4
1
R
a
n
d
o
m
i
s
e
d
,
 
d
o
u
b
l
e
-
 
b
l
i
n
d
,
 
p
l
a
c
e
b
o
-
 
c
o
n
t
r
o
l
l
e
d
 
t
r
i
a
l
6
-
w
e
e
k
P
a
t
i
e
n
t
s
 
h
o
s
p
i
t
a
l
i
z
e
d
 
f
o
r
 
a
c
u
t
e
 
e
x
a
c
e
r
b
a
t
i
o
n
 
o
f
 
D
S
M
-
I
v
 
s
c
h
i
z
o
p
h
r
e
n
i
a
5
0
0
 
p
a
t
i
e
n
t
s
4
0
 
m
g
/
d
a
y
N
 
=
 
1
2
1
8
0
 
m
g
/
d
a
y
N
 
=
 
1
1
8
1
2
0
 
m
g
/
d
a
y
N
 
=
 
1
2
3
–
P
l
a
c
e
b
o
N
 
=
 
1
2
4
P
r
i
m
a
r
y
:
 
P
A
N
S
S
 
t
o
t
a
l
 
s
c
o
r
e
S
e
c
o
n
d
a
r
y
:
 
C
l
i
n
i
c
a
l
 
G
l
o
b
a
l
 
I
m
p
r
e
s
s
i
o
n
-
S
e
v
e
r
i
t
y
 
s
c
o
r
e
I
m
p
r
o
v
e
m
e
n
t
 
o
n
 
t
h
e
 
P
A
N
S
S
 
m
e
a
n
 
t
o
t
a
l
 
s
c
o
r
e
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
M
M
R
M
)
:
L
 
4
0
 
m
g
/
d
a
y
:
 
-
1
9
.
2
 
(
±
1
.
7
)
 
 
P
 
=
 
0
.
5
9
L
 
8
0
 
m
g
/
d
a
y
:
 
-
2
3
.
4
 
(
±
1
.
8
)
 
P
 
=
 
0
.
0
3
L
 
1
2
0
 
m
g
/
d
a
y
:
 
-
2
0
.
5
 
(
±
1
.
8
)
 
P
 
=
 
0
.
3
9
P
:
 
-
1
7
.
0
 
(
±
 
1
.
8
)
D
1
0
5
0
2
3
1
,
P
E
A
R
L
 
2
M
e
l
t
z
e
r
 
H
Y
,
 
e
t
 
a
l
2
0
1
1
4
1
,
4
5
,
4
6
R
a
n
d
o
m
i
s
e
d
,
 
d
o
u
b
l
e
-
 
b
l
i
n
d
,
 
p
l
a
c
e
b
o
 
a
n
d
 
a
c
t
i
v
e
 
c
o
n
t
r
o
l
l
e
d
 
t
r
i
a
l
6
-
w
e
e
k
P
a
t
i
e
n
t
s
 
h
o
s
p
i
t
a
l
i
z
e
d
 
f
o
r
 
a
c
u
t
e
 
e
x
a
c
e
r
b
a
t
i
o
n
 
o
f
 
D
S
M
-
I
v
 
s
c
h
i
z
o
p
h
r
e
n
i
a
4
7
8
 
p
a
t
i
e
n
t
s
4
0
 
m
g
/
d
a
y
N
 
=
 
1
1
8
1
2
0
 
m
g
/
d
a
y
N
 
=
 
1
1
8
O
l
a
n
z
a
p
i
n
e
 
(
O
)
 
1
5
 
m
g
/
d
a
y
N
 
=
 
1
2
1
P
l
a
c
e
b
o
 
N
 
=
 
1
1
4
P
r
i
m
a
r
y
:
 
P
A
N
S
S
 
t
o
t
a
l
 
s
c
o
r
e
S
e
c
o
n
d
a
r
y
:
 
C
l
i
n
i
c
a
l
 
G
l
o
b
a
l
 
I
m
p
r
e
s
s
i
o
n
-
S
e
v
e
r
i
t
y
 
s
c
o
r
e
I
m
p
r
o
v
e
m
e
n
t
 
o
n
 
t
h
e
 
P
A
N
S
S
 
m
e
a
n
 
t
o
t
a
l
 
s
c
o
r
e
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
M
M
R
M
)
:
L
 
4
0
 
m
g
/
d
a
y
:
 
-
2
5
.
7
 
(
±
2
.
0
)
 
P
 
=
 
0
.
0
0
2
L
 
1
2
0
 
m
g
/
d
a
y
:
 
-
2
3
.
6
 
(
±
2
.
1
)
 
P
 
=
 
0
.
0
2
2
O
:
 
-
2
8
.
7
 
(
±
1
.
9
)
 
P
 
,
 
0
.
0
0
1
P
:
 
-
1
6
.
0
 
(
±
2
.
1
)
(
C
o
n
t
i
n
u
e
d
)
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
161
Lurasidone in the management of schizophreniaNeuropsychiatric Disease and Treatment 2012:8
T
a
b
l
e
 
2
 
(
C
o
n
t
i
n
u
e
d
)
S
t
u
d
y
 
(
y
e
a
r
 
o
f
 
p
u
b
l
i
c
a
t
i
o
n
)
T
y
p
e
 
o
f
 
s
t
u
d
y
 
a
n
d
 
d
u
r
a
t
i
o
n
 
(
w
e
e
k
s
)
D
i
a
g
n
o
s
e
s
 
a
n
d
 
n
u
m
b
e
r
 
o
f
 
r
a
n
d
o
m
i
s
e
d
 
p
a
t
i
e
n
t
s
L
u
r
a
s
i
d
o
n
e
 
r
e
g
i
m
e
n
 
(
n
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
)
A
c
t
i
v
e
 
c
o
m
p
a
r
a
t
o
r
 
r
e
g
i
m
e
n
 
(
n
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
)
P
l
a
c
e
b
o
 
(
n
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
)
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
M
a
i
n
 
e
f
fi
c
a
c
y
 
r
e
s
u
l
t
s
 
(
p
r
i
m
a
r
y
 
o
u
t
c
o
m
e
s
)
D
1
0
5
0
2
3
3
,
P
E
A
R
L
 
3
4
1
R
a
n
d
o
m
i
s
e
d
,
 
d
o
u
b
l
e
-
 
b
l
i
n
d
,
 
p
l
a
c
e
b
o
 
a
n
d
 
a
c
t
i
v
e
 
c
o
n
t
r
o
l
l
e
d
 
t
r
i
a
l
6
-
w
e
e
k
P
a
t
i
e
n
t
s
 
h
o
s
p
i
t
a
l
i
z
e
d
 
f
o
r
 
a
c
u
t
e
 
e
x
a
c
e
r
b
a
t
i
o
n
 
o
f
 
D
S
M
-
I
v
 
 
s
c
h
i
z
o
p
h
r
e
n
i
a
4
8
8
 
p
a
t
i
e
n
t
s
8
0
 
m
g
/
d
a
y
N
 
=
 
1
2
5
1
6
0
 
m
g
/
d
a
y
N
 
=
 
1
2
1
Q
u
e
t
i
a
p
i
n
e
 
(
O
)
 
X
R
 
6
0
0
 
m
g
/
d
a
y
N
 
=
 
1
1
6
P
l
a
c
e
b
o
N
 
=
 
1
2
0
P
r
i
m
a
r
y
:
 
P
A
N
S
S
 
t
o
t
a
l
 
s
c
o
r
e
S
e
c
o
n
d
a
r
y
:
 
C
l
i
n
i
c
a
l
 
G
l
o
b
a
l
 
I
m
p
r
e
s
s
i
o
n
-
S
e
v
e
r
i
t
y
 
s
c
o
r
e
I
m
p
r
o
v
e
m
e
n
t
 
o
n
 
t
h
e
 
P
A
N
S
S
 
m
e
a
n
 
t
o
t
a
l
 
s
c
o
r
e
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
M
M
R
M
)
:
L
 
8
0
 
m
g
/
d
a
y
:
 
-
2
2
.
2
 
P
 
,
 
0
.
0
0
1
L
 
1
6
0
 
m
g
/
d
a
y
:
 
-
2
6
.
5
 
P
 
,
 
0
.
0
0
1
O
:
 
-
2
7
.
8
 
P
 
,
 
0
.
0
0
1
P
:
 
-
1
0
.
3
C
u
c
c
h
i
a
r
o
 
J
,
 
e
t
 
a
l
4
7
R
a
n
d
o
m
i
s
e
d
,
 
d
o
u
b
l
e
-
 
b
l
i
n
d
,
 
a
c
t
i
v
e
 
c
o
n
t
r
o
l
l
e
d
 
t
r
i
a
l
3
-
w
e
e
k
S
t
a
b
l
e
 
o
u
t
p
a
t
i
e
n
s
 
w
i
t
h
 
c
h
r
o
n
i
c
 
s
c
h
i
z
o
p
h
r
e
n
i
a
 
o
r
 
 
s
c
h
i
z
o
a
f
f
e
c
t
i
v
e
 
d
i
s
o
r
d
e
r
s
3
0
1
 
p
a
t
i
e
n
t
s
1
2
0
 
m
g
/
d
a
y
N
 
=
 
1
5
0
Z
i
p
r
a
s
i
d
o
n
e
 
(
Z
)
 
8
0
 
m
g
 
B
I
D
N
 
=
 
1
5
1
–
P
r
i
m
a
r
y
:
 
P
A
N
S
S
 
t
o
t
a
l
 
s
c
o
r
e
S
e
c
o
n
d
a
r
y
:
 
C
l
i
n
i
c
a
l
 
G
l
o
b
a
l
 
I
m
p
r
e
s
s
i
o
n
-
S
e
v
e
r
i
t
y
 
s
c
o
r
e
I
m
p
r
o
v
e
m
e
n
t
 
o
n
 
t
h
e
 
P
A
N
S
S
 
m
e
a
n
 
t
o
t
a
l
 
s
c
o
r
e
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
M
M
R
M
)
:
L
 
1
2
0
 
m
g
/
d
a
y
:
 
-
6
.
2
 
P
 
,
 
0
.
0
5
Z
:
 
-
4
.
5
 
P
 
,
 
0
.
0
5
F
a
i
l
e
d
 
t
r
i
a
l
D
1
0
5
0
0
4
9
4
1
R
a
n
d
o
m
i
s
e
d
,
 
d
o
u
b
l
e
-
 
b
l
i
n
d
,
 
p
l
a
c
e
b
o
 
a
n
d
 
a
c
t
i
v
e
 
c
o
n
t
r
o
l
l
e
d
 
t
r
i
a
l
6
-
w
e
e
k
P
a
t
i
e
n
t
s
 
h
o
s
p
i
t
a
l
i
z
e
d
 
f
o
r
 
a
c
u
t
e
 
e
x
a
c
e
r
b
a
t
i
o
n
 
o
f
 
D
S
M
-
I
v
 
s
c
h
i
z
o
p
h
r
e
n
i
a
3
5
6
 
p
a
t
i
e
n
t
s
2
0
 
m
g
/
d
a
y
N
 
=
 
7
1
4
0
 
m
g
/
d
a
y
N
 
=
 
6
7
8
0
 
m
g
/
d
a
y
N
 
=
 
7
1
H
a
l
o
p
e
r
i
d
o
l
 
(
H
)
 
1
0
 
m
g
/
d
a
y
N
 
=
 
7
2
P
l
a
c
e
b
o
N
 
=
 
7
2
P
r
i
m
a
r
y
:
 
B
P
R
S
 
t
o
t
a
l
 
s
c
o
r
e
S
e
c
o
n
d
a
r
y
:
 
P
A
N
S
S
 
t
o
t
a
l
 
s
c
o
r
e
;
C
l
i
n
i
c
a
l
 
G
l
o
b
a
l
 
I
m
p
r
e
s
s
i
o
n
-
 
S
e
v
e
r
i
t
y
 
s
c
o
r
e
;
 
C
l
i
n
i
c
a
l
 
G
l
o
b
a
l
 
I
m
p
r
e
s
s
i
o
n
-
I
m
p
r
o
v
e
m
e
n
t
 
s
c
o
r
e
I
m
p
r
o
v
e
m
e
n
t
 
o
n
 
t
h
e
 
m
e
a
n
 
B
P
R
S
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
L
O
C
F
)
:
L
 
2
0
 
m
g
/
d
a
y
:
 
-
5
.
0
 
(
±
1
.
4
)
 
P
 
=
 
0
.
3
6
L
 
4
0
 
m
g
/
d
a
y
:
 
-
5
.
2
 
(
±
1
.
4
)
 
P
 
=
 
0
.
4
4
L
 
8
0
 
m
g
/
d
a
y
:
 
-
8
.
0
 
(
±
1
.
4
)
 
P
 
=
 
1
.
0
0
H
:
 
-
9
.
8
 
(
±
1
.
4
)
 
P
 
=
 
0
.
7
5
P
:
 
-
7
.
9
 
(
±
1
.
4
)
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
L
,
 
l
u
r
a
s
i
d
o
n
e
;
 
H
,
 
h
a
l
o
p
e
r
i
d
o
l
;
 
Z
,
 
z
i
p
r
a
s
i
d
o
n
e
;
 
P
,
 
p
l
a
c
e
b
o
;
 
B
P
R
S
,
 
b
r
i
e
f
 
p
s
y
c
h
i
a
t
r
i
c
 
r
a
t
i
n
g
 
s
c
a
l
e
;
 
P
A
N
S
S
,
 
p
o
s
i
t
i
v
e
 
a
n
d
 
n
e
g
a
t
i
v
e
 
s
y
n
d
r
o
m
e
 
s
c
a
l
e
;
 
L
O
C
F
,
 
l
a
s
t
 
o
b
s
e
r
v
a
t
i
o
n
 
c
a
r
r
i
e
d
 
f
o
r
w
a
r
d
;
 
M
M
R
M
,
 
m
i
x
e
d
-
e
f
f
e
c
t
 
m
o
d
e
l
 
r
e
p
e
a
t
e
d
 
m
e
a
s
u
r
e
;
 
P
E
A
R
L
,
 
P
r
o
g
r
a
m
 
t
o
 
E
v
a
l
u
a
t
e
 
t
h
e
 
A
n
t
i
p
s
y
c
h
o
t
i
c
 
R
e
s
p
o
n
s
e
 
t
o
 
L
u
r
a
s
i
d
o
n
e
.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
162
Caccia et alNeuropsychiatric Disease and Treatment 2012:8
haloperidol (10 mg/day) differed from placebo in their effects 
on the psychopathological outcome measures.41
The long-term efficacy of lurasidone in schizophrenia has 
been evaluated in the extension phase of some short-term 
studies, but results have not been published. Data on the 
maintenance of clinical effect of lurasidone in schizophrenia 
patients treated for up to 8 months in the program to evaluate 
the antipsychotic response to lurasidone (PEARL) 2 exten-
sion trial were encouraging.29,50
No consistent data are available for assessing the   efficacy 
of lurasidone in depressive symptoms associated with 
schizophrenia. The only significant improvement in patient 
depression that has been reported following lurasidone 
treatment was a secondary analysis of a trial evaluating the 
efficacy of lurasidone in patients with schizophrenia who 
were experiencing depressive symptoms according to the 
Montgomery–Asberg depression rating scale.51
A recent review discussed the limitations of data on 
efficacy, particularly the lack of response rates for the active 
comparator, the different definitions for response from one 
study to another, the inclusion of patients quite different from 
those encountered in clinical practice, and the data sources 
(most clinical data are from abstracts or posters, and very 
few reports have been published in peer reviewed medical 
journals).29
Safety and tolerability
Common adverse events
Preliminary information, mainly disclosed in study reports 
and posters, suggests that lurasidone is well tolerated, with a 
lower discontinuation rate than placebo. The drug’s short-term 
safety profile has been evaluated in randomized double blind 
phase II and phase III trials of 3 to 6 weeks’ duration, one 
of which included 1004 lurasidone-treated and 455 placebo-
treated patients. Active comparators were haloperidol, ziprasi-
done, risperidone, quetiapine, and olanzapine.29,52,53 Only three 
short term clinical trials have been published; the main adverse 
drug reactions are reported in Table 3.43–45 Safety data based 
on pooled analyses from five short-term, placebo-controlled 
studies covered 1004 lurasidone-treated patients and 455 
placebo-treated patients.52,54 The most   frequent adverse 
events (incidence $5%) were akathisia (15%), nausea (12%), 
sedation (12%), somnolence (11%), Parkinsonism (11%), 
insomnia (8%), agitation (6%), anxiety (6%), and dystonia 
(5%). Pooled analyses indicate that 8% of the lurasidone 
group and 4% of the placebo group discontinued treatment 
due to adverse events, with no dose-related differences in 
the 40–120 mg⁄day range. Apparent dose-related adverse 
  reactions were akathisia and somnolence. Other common 
adverse events did not appear to be dose-related.
Long-term safety data are available only in manufac-
turer’s communications.50 Compared to risperidone, lur-
asidone had a favorable safety profile at 12 months, with a 
significantly lower incidence of somnolence, constipation, 
and weight gain. Akathisia, nausea, and vomiting were more 
frequent with lurasidone, which is similar to the results of a 
short-term quetiapine and olanzapine trial.42,45,50
Extrapyramidal symptoms and akathisia
In the short-term clinical trials, EPS, akathisia, and dystonia 
were more frequent in lurasidone-treated patients (14.7%, 
15%, and 4.7%, respectively) than in the placebo group (5.1%, 
3.3%, and 0.7%, respectively). However, the mean changes 
from baseline were similar for EPS and dyskinesias, and very 
close to placebo for akathisia (0.2 for lurasidone and 0.0 for 
placebo).42,52–55 Lurasidone was not significantly associated 
with movement disorders, and EPS (including dystonia) 
was seen at the highest dose of lurasidone (120 mg/day).53 
However, patients treated with lurasidone required more anti-
cholinergic medications (23%) than those treated with olan-
zapine (18%) and placebo (11%), though less than haloperidol 
(53%).55 Only akathisia appeared to be dose-related. In a long-
term comparative trial with risperidone, akathisia occurred 
in 14.3% of lurasidone-treated patients (40–120 mg/day) and 
7.9% of risperidone-treated patients.50,53
QT interval
In the short-term lurasidone trials, there were no reports of 
increases in QTc .500 msec and no electrocardiographic 
abnormalities.44,53–55 When compared with ziprasidone over 
a 3-week period, no clinically significant elevations in QTc 
were reported, and lurasidone was associated with a smaller 
change in QTc than ziprasidone (+0.3 msec and +3.3 msec, 
respectively).43 Compared to olanzapine and placebo, mean 
changes in QTc were similar for lurasidone 40 and 120 mg/day 
(+5.1 and +4.5 msec, respectively), olanzapine (+4.4 msec) 
and placebo (+3.8 msec).45 The percentage of women was 
very low in both studies (30% for lurasidone and 29.1% for 
ziprasidone in the first study;43 22% and 21% for lurasidone 
40 and 120 mg/day, 22% for olanzapine, and 23% for placebo 
in the second study),45 which may be significant as gender is a 
risk factor for QTc prolongation and torsades des pointes.
Metabolic side effects
No significant metabolic effects were reported for 
  lurasidone. In the pooled analyses from five short-term, 
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Table 3 Main adverse drug reactions reported in published clinical trials
Short term phase II trial (6 weeks)44
Lurasidone 80 mg/day 
(n = 90)
Placebo  
(n = 90)
EPS (%) NA NA
Akathisia (%) 8.9 3.3
Mean changes from baseline
QTc prolongation ± SD (msec) -1.2 ± 17.3 +0.9 ± 16.7
weight gain (kg)* +0.9 +0.5
Total cholesterol (mg/dL) -10.1 ± NA -7.1 ± NA
Triglycerides (mg/dL) -24.4 -31.7 ± NA
Glucose (mg/dL) +2.9 ± NA +3.4 ± NA
Prolactin (ng/mL)* +2.4 -0.3
Short-term phase III efficacy and safety trials (6 weeks)45
Lurasidone 40 mg/day  
(n = 119)
Lurasidone 120 mg/day 
(n = 118)
Olanzapine 15 mg/day 
(n = 122)
Placebo 
(n = 114)
Parkinsonism (%) 9.2 11.0 4.9 1.7
Tremor (%) 1.7 7.6 5.7 4.3
Dystonia (%) 3.4 7.6 0.8 0.9
Akathisia (%) 11.8 22.9 7.4 0.9
Mean changes from baseline
QTc prolongation ± SD (msec) +5.1 ± NA +4.5 ± NA +4.4 ± NA +3.8 ± NA
weight gain ± SD (kg) +1.0 ± 2.9 +1.0 ± 2.2 +4.1 ± 4.3 +0.6 ± 2.7
Total cholesterol ± SD (mg/dL) -8.6 ± 29.8 -7.3 ± 25.3 +9.6 ± 31.2 -6.8 ± 28.7
Triglycerides ± SD (mg/dL) -8.3 ± 76.2 -5.0 ± 85.5 50.0 ± 115.0 0.1 ± 64.8
Glucose ± SD (mg/dL) 0.0 ± 19.2 +0.5 ± 20.9 +10.3 ± 34.8 +0.4 ± 24.6
Prolactin ± SD (ng/L) +2.1 ± 13.9 +10.9 ± 28.1 +5.0 ± 12.2 -2.5 ± 16.9
Short-term phase III efficacy and safety trials (3 weeks)43
Lurasidone 120 mg/day 
(n = 150)
Ziprasidone 160 mg/day 
(n = 151)
EPS (%) 3.3 1.3
Akathisia (%) 3.3 6.6
Mean changes from baseline
QTc prolongation ± SD (msec) +0.3 ± 19.4 +3.3 ± 18.1
weight gain ± SD (kg) -0.27 ± 1.7 -0.41 ± 3.2
Total cholesterol ± SD (mg/dL) -6.4 ± 24.0 -4.4 ± 30.4
Triglycerides ± SD (mg/dL) -2.6 ± 86.6 +22.4 ± 258.8
Glucose ± SD (mg/dL) +4.7 ± 20.8 +4.8 ± 25.0
Prolactin ± SD (ng/mL)* +3.0 +2.0
Note: *Only median changes were available.
Abbreviations: EPS, extrapyramidal symptoms; NA, not available.
  placebo-controlled trials, mean increases in fasting glucose 
were 1.4 mg/dL in the lurasidone group and 0.6 mg/dL 
in the placebo group, but these changes were not statisti-
cally different. Short-term placebo-controlled trials and 
  uncontrolled long-term trials found no dose-response rela-
tionship in the lurasidone group for mean changes in glucose 
levels.54 In clinical trials with an active comparator, changes 
in glucose were similar for lurasidone and ziprasidone (+4.7 
and +4.8 mg/dL, respectively); glucose was also unchanged 
in lurasidone and placebo treated patients (+1.0 mg/dL) 
but higher in olanzapine and haloperidol-treated patients 
(+4.0 mg/dL and +2.0 mg/dL, respectively).43 In a long-term 
trial in comparison with risperidone, lurasidone lowered 
glucose by 0.5 mg/dL from baseline, while risperidone 
raised it by 3.0 mg/dL.50
No increases were reported in total cholesterol, low-density 
lipoprotein cholesterol, or triglycerides in short-term trials 
comparing lurasidone with placebo.52,53 Mean changes in total 
cholesterol and triglycerides in uncontrolled long-term studies 
were -4.2 and -13.6 mg/dL, respectively, at week 24, -1.9 and 
-3.5 mg/dL, respectively, at week 36, and -3.6 and -6.5 mg/dL, 
respectively, at week 52.54 In short-term controlled studies, 
lurasidone was associated with a reduction in triglycerides 
(-2.6 mg/dl) while ziprasidone was associated with an increase 
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(+22.4 mg/dL), but no difference was reported for mean change 
in total cholesterol (-6.4 and -4.4 mg/dL, respectively).43 In 
controlled clinical trials with placebo and olanzapine, mean 
changes in total cholesterol were comparable for lurasidone 
40 mg/day, 120 mg/day, and placebo group (-8.6, -7.3, and 
-6.8 mg/dL, respectively), while there was a significant increase 
in the olanzapine group (+9.6 mg/dL). Mean triglyceride levels 
decreased with lurasidone (-8.3 and -5.0 mg/dL for lurasidone 
40 and 120 mg/day, respectively), increased for olanzapine 
treated patients (+50.0 mg/dL) and remained unchanged in 
the placebo group (+0.1 mg/dL).45 In the pooled analyses from 
five short-term, placebo-controlled trials, mean changes in 
total cholesterol and triglycerides were similar for lurasidone 
(-8.0 and -5.0 mg/dL, respectively), haloperidol (-8.0 and 
-3.0 mg/dL, respectively), and placebo (-10.0 and -7.0 mg/dL, 
respectively).52,53 In a 6-week randomized   clinical trial compar-
ing lurasidone with placebo and   quetiapine, lurasidone reduced 
triglyceride levels to a similar level to placebo (-9.0 mg/dL 
for placebo, and -2.0 and -9.0 mg/dL for lurasidone 80 and 
160 mg/day, respectively), while quetiapine raised triglyceride 
levels (+8.0 mg/dL).53,54 In a long-term controlled trial with ris-
peridone, the median reduction from baseline for lipid variables 
was similar in lurasidone and risperidone groups.50
weight gain
The overall effects of lurasidone on body weight appear to be 
minimal. Short-term clinical trials showed a mean weight gain 
of 0.75 kg in the lurasidone group and 0.26 kg in the placebo 
group. The proportion of patients with weight gain, defined 
as an increase of more than 7% in body weight, was similar 
for lurasidone, haloperidol, and placebo (5.6%, 4.2%, and 4% 
respectively).52,53 The proportion of patients with clinically sig-
nificant weight gain was similar for lurasidone (7.6% for 40 mg 
and 7.0% for 120 mg) and placebo (4.2%), but higher (34.4%) 
in the olanzapine group. The mean increase in body weight was 
higher for olanzapine (4.1 kg) than with placebo (0.6 kg) and 
lurasidone (1.0 kg). The effect did not appear to be dose-related 
(1.0 kg for both lurasidone 40 mg and 120 mg).45 Another study 
found that weight gain was similar with lurasidone and placebo 
(0.6 kg and 0.1 kg), but higher for quetiapine-treated patients 
(2.1 kg).54 Mean changes in weight were also similar for lurasi-
done and ziprasidone (-0.29 kg and -0.16 kg, respectively),43 
a finding which is of interest as ziprasidone is an antipsychotic 
associated with a low risk of weight gain, but long-term data 
are limited. Effects on body weight were also minimal in a 
long-term randomized clinical trial where the mean change in 
weight was -0.9 kg in the lurasidone group and +2.6 kg in the 
risperidone group after 12 months.50
Hyperprolactinemia
Lurasidone can raise prolactin levels, with a dose-dependent 
relationship in short-term clinical trials.   Hyperprolactinemia 
was slightly greater in female patients. In the pooled 
analysis of short-term placebo-controlled trials, the mean 
change in prolactin levels from baseline was significantly 
different from placebo: +1.1 ng/mL for lurasidone-treated 
patients (0.3 ng/mL for 40 mg and 3.4 ng/ml for 120 mg) 
and -0.6 ng/mL for placebo-treated patients.52 Mean changes 
in   prolactin levels were greater in patients treated with 
haloperidol (+8.5 ng/mL), than with olanzapine, lurasidone, 
and placebo (+3.7 ng/mL, +1.1 ng/mL, and -0.5 ng/mL, 
respectively).55 The increase in prolactin level for lurasidone 
120 mg/day (+10.9 ng/mL) was significantly greater than 
with olanzapine (+5.0 ng/ml) or placebo (-2.5 ng/ml).45 
Compared to ziprasidone, the median increase in prolactin 
was significantly greater in the lurasidone group (2.0 ng/mL 
and 3.0 ng/mL, respectively).43 No symptoms were reported 
in either study, and no patients discontinued study medication 
because of high prolactin levels.43,45 Compared to risperi-
done, median increases from baseline at 12 months were 
0.10 ng/mL for lurasidone and 9.10 ng/mL for   risperidone.50 
Uncontrolled long-term trials reported no increase in prolac-
tin concentrations: lurasidone was associated with a change 
in prolactin of -1.9 ng/mL at week 24, -5.4 ng/mL at week 
36, and -3.3 ng/mL at week 52.42
Dosing schedules
Lurasidone hydrochloride has been shown to be effective in 
a dose range of 20 to 120 mg/day, although the lowest dose 
was less effective in terms of improvement in schizophrenia 
symptoms. Six-week controlled trials, however, have found 
no suggestion of added benefit with 120 mg/day. There was 
a dose-related increase in certain adverse reactions (in par-
ticular somnolence and EPS), with greater discontinuation 
rates due to adverse events at the higher doses. Therefore, 
the maximum recommended dose is 80 mg/day.42
In clinical practice, lurasidone is given orally once daily, 
with the recommended starting dose of 40 mg/day, taken 
with food (at least 350 calories), with no initial dose titration 
required. Dose adjustments are not required on the basis of 
age, sex, or race, but for patients with moderate to severe 
renal or hepatic impairment the dose of lurasidone hydro-
chloride should not exceed 40 mg/day. The relatively long 
t1/2 in comparison to many other atypical antipsychotics30,31 
allows once-daily administration. Theoretically, this may 
result in low fluctuations in steady-state concentrations of the 
parent drug and its active metabolites in plasma and target 
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sites, although it would be useful to characterize the rate of 
elimination and extent of accumulation of the parent drug and 
its active metabolites in the various patient populations.
The dose should also not exceed 40 mg/day when 
  lurasidone hydrochloride is co-administered with moderate 
CYP3A4 inhibitors such as diltiazem. Co-administration 
with potent inhibitors of hepatic and intestinal CYP3A4 such 
as ketoconazole and grapefruit juice or CYP3A4 inducers 
such as rifampin and high-hyperforin extracts of Hypericum 
perforatum is contraindicated.42
Place of lurasidone in therapy
Lurasidone is similar to many older antipsychotics in its affin-
ity for D2 and 5-HT2A and, as with atypical agents, it exerts 
antipsychotic activity with a limited risk of EPS. On the basis 
of its potent antagonism of 5-HT7 and high affinity for other 
receptors implicated in the enhance  ment of cognitive func-
tion, particularly 5-HT1A at which is acts as a partial agonist, 
lurasidone was hypothesized to have favorable effects on 
cognition, memory, and mood, although this hypothesis is 
not currently supported by clinical evidence. The drug is also 
expected to possess anxiolytic- or antidepressant-like activity 
in clinical use because of its higher affinities for 5-HT7 and 
5-HT1A receptors. Moreover, it shows little binding affinity 
for α1-adrenergic receptors, suggesting that it should have 
a low risk for orthostatic hypotension and sedation.
Affinity at the histamine H1 and muscarinic M1 receptors 
was also very low, which supports a favorable side-effect 
profile for this drug. Clinical trials to date indicate that the 
most common adverse events associated with lurasidone 
are mild akathisia, sedation, and Parkinsonism. The rates 
of these events are low and dose-related. Early data also 
showed minimal risks for weight gain and metabolic abnor-
malities, similar to some other new antipsychotics such as 
aripiprazole, iloperidone, and ziprasidone. Additionally, 
there are only minimal increases in prolactin levels with no 
significant increases in QTc, which is in contrast to iloperi-
done and ziprasidone. This may give lurasidone an advantage 
over some atypical antipsychotics, but further trials with a 
broader population of patients would be useful to explore 
these areas.
Although lurasidone was effective and generally well 
tolerated in several short-term placebo controlled trials, these 
enrolled only small numbers of highly selected patients, and 
studies that compared lurasidone with an active comparator 
were not designed to directly test the differences among 
antipsychotics. These weaknesses limit the general exten-
sion of the results to patients with other psychological or 
clinical comorbidities, those with comorbid drug use and/
or dependence, patients who are resistant to treatment with 
other antipsychotics, and adolescents or elderly patients. 
Moreover, data are limited on lurasidone’s effectiveness in 
the maintenance treatment of schizophrenia. The only data 
on the drug’s long-term efficacy come from the extension 
phase of some short-term studies.
Although none of the patients treated with lurasidone 
experienced significant QTc change, electrocardiographic 
changes for haloperidol and ziprasidone, which are included 
in the list of drugs associated with the risk of torsades 
de pointes, are lower than expected.56–58 However, to date 
  lurasidone has been tested in a small sample of patients and 
the risk of torsades de pointes in the general populations 
remains unknown. Additional studies on larger samples of 
patients are therefore required. Lurasidone also appears to 
have a low potential for causing weight gain and adverse 
metabolic effects, but longer-term trials are needed to assess 
the risk of new-onset diabetes, which is of particular concern 
with second-generation antipsychotics.59,60 Long-term treat-
ment with antipsychotic drugs, especially at high dosages, is 
also associated with the risk of tardive dyskinesia, and this 
potential adverse reaction may be underestimated because 
of the limited information available at this time from long-
term clinical trials.
When compared with other recent second-generation 
antipsychotics that also have a low propensity for causing 
the adverse effects of older antipsychotics, lurasidone has 
further potential advantages including once-daily admin-
istration (unlike the twice-daily administration required 
for asenapine, iloperidone, and ziprasidone) and the 
fact that dosing titration is not necessary (in contrast to 
asenapine, iloperidone, sertindole, and ziprasidone).25,61–63 
Lurasidone’s advantage of once-daily dosing (which is 
shared by the long t1/2 aripiprazole and sertindole, among 
the newer antipsychotics),30, 62 should also help improve 
patient compliance.
Beneficial features of lurasidone include the lack of clini-
cally significant age-, sex-, or race-related effects.28,30,41 These 
results must, however, be extended to its active metabolites, 
whose pharmacological and pharmacokinetic profiles and 
potential contributions to the overall outcome are still largely 
unknown.
Although clinicians will need to consider lurasidone’s 
favorable side-effect profile when making a therapeutic deci-
sion, this new antipsychotic has some disadvantages. Whereas 
food does not significantly affect the absorption of most 
antipsychotics, lurasidone must be administered carefully in 
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relation to meals in order to optimize bioavailability (another 
exception is ziprasidone, although this has a higher caloric 
threshold than lurasidone).28,63 Dose adjustment is recom-
mended in moderate and severe renal or hepatic impair-
ment, in contrast to the dose reductions recommended for 
paliperidone in renal impairment and for iloperidone and 
sertindole in hepatic impairment, while no adjustments are 
needed for aripiprazole and ziprasidone.25,30,62 Being primarily 
biotransformed by CYP3A4, co-administration with strong 
inducers and inhibitors of CYP3A4 is con  traindicated, a 
disadvantage shared by most of the newer lipophilic anti-
psychotics, although carbamazepine and ketoconazole 
have less effect on the clearance of antipsychotics that have 
significant alternative pathways (for example, ziprasidone 
is partly metabolized by aldehyde oxidase, while paliperi-
done’s clearance is largely due to urinary excretion of the 
drug itself). Unlike aripiprazole, iloperidone, sertindole, 
and many older antipsychotics, however, lurasidone does not 
present any of the polymorphic metabolism characteristics 
mirroring the CYP2D6 phenotype,25,30,62 and can therefore 
be administered in combination with CYP2D6 inhibitors, 
regardless of patient’s genetic status.41,42
Lastly, the clinical advantages of the new antipsychotic 
agents have not been well evaluated in direct superiority 
comparative studies. The lack of well-designed long-term 
comparative studies and the unnecessary and excessive use 
of placebo in the few short-term studies that are available 
add to the difficulty of establishing the place of lurasidone 
and the other new agents in therapy, and providing clinicians 
with clear guidance on the choice of the best treatment for 
each patient. Well-designed and appropriately powered clini-
cal studies are now needed to assess the therapeutic role of 
lurasidone in schizophrenia.
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